.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,718,608

« Back to Dashboard

Claims for Patent: 7,718,608

Title:Methods of treating a subject suffering from irritable bowel syndrome
Abstract: Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome.
Inventor(s): Lin; Henry C (Manhattan Beach, CA), Pimentel; Mark (Los Angeles, CA)
Assignee: Cedars-Sinai Medical Center (Los Angeles, CA)
Application Number:12/234,502
Patent Claims: 1. A method of treating a subject suffering from irritable bowel syndrome, comprising administering rifaximin to the subject, wherein said administration reduces the symptoms of irritable bowel syndrome.

2. The method of claim 1, wherein the rifaximin is administered orally.

3. The method of claim 1, wherein the rifaximin is administered in a unitized amount.

4. The method of claim 1, wherein the rifaximin is dehydrated rifaximin.

5. The method of claim 1, wherein the rifaximin is lyophilized rifaximin.

6. The method of claim 1, wherein the administering reduces the symptoms of irritable bowel syndrome based on visual analog scores.

7. The method of claim 1, wherein the administering reduces extraintestinal symptoms of irritable bowel syndrome.

8. The method of claim 7, wherein the extraintestinal symptoms include joint pain and fatigue.

9. The method of claim 1, wherein the administering results in at least partial eradication of the small intestinal bacterial overgrowth.

10. The method of claim 1, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

11. The method of claim 1, wherein the administering comprises swallowing the rifaximin.

12. The method of claim 1, wherein the rifaximin is administered at room temperature.

13. The method of claim 1, wherein the rifaximin is administered at a refrigerated temperature.

14. The method of claim 1, further comprising administering an intestinal lavage or enema.

15. A method of improving the symptoms of a subject suffering from irritable bowel syndrome, comprising administering rifaximin to the subject, wherein said administration improves the symptoms of irritable bowel syndrome.

16. The method of claim 15, wherein the rifaximin is administered orally.

17. The method of claim 15, wherein the rifaximin is administered in a unitized amount.

18. The method of claim 15, wherein the rifaximin is dehydrated rifaximin.

19. The method of claim 15, wherein the rifaximin is lyophilized rifaximin.

20. The method of claim 15, wherein the improvement of irritable bowel syndrome is based on visual analog scores.

21. The method of claim 15, wherein the improvement further comprises improvement of extraintestinal symptoms of irritable bowel syndrome.

22. The method of claim 21, wherein the extraintestinal symptoms include joint pain and fatigue.

23. The method of claim 15, wherein the administering results in at least partial eradication of the small intestinal bacterial overgrowth.

24. The method of claim 15, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

25. The method of claim 15, wherein the improvement in symptoms of irritable bowel syndrome is greater than 90%.

26. The method of claim 15, wherein the administration of rifaximin comprises swallowing the rifaximin.

27. The method of claim 15, wherein the rifaximin is administered at room temperature.

28. The method of claim 15, wherein the rifaximin is administered at a refrigerated temperature.

29. The method of claim 15, further comprising administering an intestinal lavage or enema.

30. A method of treating a subject suffering from irritable bowel syndrome, comprising: providing a therapeutic regime that includes an antimicrobial agent, wherein the antimicrobial agent comprises rifaximin; and administering the therapeutic regime to the subject to improve symptoms related to irritable bowel syndrome.

31. The method of claim 30, wherein the therapeutic regime is administered orally.

32. The method of claim 30, wherein the therapeutic regime is administered in a unitized amount.

33. The method of claim 30, wherein the rifaximin is dehydrated rifaximin.

34. The method of claim 30, wherein the rifaximin is lyophilized rifaximin.

35. The method of claim 30, wherein the therapeutic regime improves symptoms of irritable bowel syndrome based on visual analog scores.

36. The method of claim 30, wherein the improvement of symptoms further comprises improvement of extraintestinal symptoms of irritable bowel syndrome.

37. The method of claim 36, wherein the extraintestinal symptoms include joint pain and fatigue.

38. The method of claim 30, wherein the administering results in at least partial eradication of the small intestinal bacterial overgrowth.

39. The method of claim 30, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

40. The method of claim 30, wherein the improvement of symptoms related to irritable bowel syndrome is greater than 90%.

41. The method of claim 30, wherein the administration of the therapeutic regime comprises swallowing the rifaximin.

42. The method of claim 30, wherein the therapeutic regime is administered at room temperature.

43. The method of claim 30, wherein the therapeutic regime is administered at a refrigerated temperature.

44. The method of claim 30, further comprising administering an intestinal lavage or enema.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc